Xenogen Biosciences will utilize its Serial Phenotyping Compression Technology (SPCT) to characterize targets from Schering-Plough Research Institute’s drug discovery research.

SPCT evaluates the physiological and behavioral impact of the targets by utilizing a battery of more than 85 pharmacologically-validated bioassays and covering several therapeutic areas, according to Xenogen. This agreement expands on a previous agreement aimed at the creation of gene knockouts.

Previous articleNIH to Conduct Clinical Trial with GenVec Vaccine in HIV Patients
Next articleStudies Demonstrate that HIV’s Effect on Cells Can Be Reversed